67,487 Shares in Denali Therapeutics Inc. $DNLI Acquired by 1492 Capital Management LLC

1492 Capital Management LLC purchased a new position in Denali Therapeutics Inc. (NASDAQ:DNLI) during the 4th quarter, HoldingsChannel reports. The firm purchased 67,487 shares of the company’s stock, valued at approximately $1,114,000.

Other hedge funds have also made changes to their positions in the company. Headlands Technologies LLC bought a new stake in Denali Therapeutics during the 2nd quarter valued at $26,000. Johnson Financial Group Inc. bought a new stake in Denali Therapeutics during the 3rd quarter valued at $29,000. State of Wyoming bought a new stake in Denali Therapeutics during the 2nd quarter valued at $29,000. Quarry LP bought a new stake in shares of Denali Therapeutics in the 3rd quarter worth $64,000. Finally, Eurizon Capital SGR S.p.A. bought a new stake in shares of Denali Therapeutics in the 4th quarter worth $83,000. Institutional investors own 92.92% of the company’s stock.

Denali Therapeutics Stock Up 1.6%

DNLI opened at $19.66 on Thursday. Denali Therapeutics Inc. has a one year low of $12.58 and a one year high of $23.77. The company has a debt-to-equity ratio of 0.01, a quick ratio of 9.28 and a current ratio of 9.28. The stock’s fifty day moving average is $19.70 and its 200-day moving average is $19.31. The company has a market capitalization of $3.12 billion, a PE ratio of -6.83 and a beta of 1.03.

Denali Therapeutics (NASDAQ:DNLI) last issued its earnings results on Thursday, May 7th. The company reported ($0.69) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.04. During the same period last year, the firm earned ($0.78) earnings per share. On average, equities analysts predict that Denali Therapeutics Inc. will post -2.74 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on DNLI shares. BTIG Research reissued a “buy” rating and issued a $39.00 price objective on shares of Denali Therapeutics in a research note on Monday, May 11th. Morgan Stanley dropped their price objective on Denali Therapeutics from $40.00 to $35.00 and set an “overweight” rating on the stock in a research note on Friday, May 22nd. Jefferies Financial Group reissued a “buy” rating and issued a $40.00 price objective on shares of Denali Therapeutics in a research note on Monday, March 2nd. The Goldman Sachs Group boosted their price objective on Denali Therapeutics from $35.00 to $40.00 and gave the stock a “buy” rating in a research note on Thursday, March 26th. Finally, Leerink Partners dropped their price objective on Denali Therapeutics from $40.00 to $35.00 and set an “outperform” rating on the stock in a research note on Wednesday, April 22nd. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $34.25.

Denali Therapeutics Profile

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.